IP Library Patent Application 18901122
Patent Application
App. No. 18/901,122

METHODS FOR DETERMINING FRACTION OF FETAL NUCLEIC ACIDS IN MATERNAL SAMPLES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/901,122
Abstract

The invention provides compositions and methods for determining the fraction of fetal nucleic acids in a maternal sample comprising a mixture of fetal and maternal nucleic acids. The fraction of fetal nucleic acids can be used in determining the presence or absence of fetal aneuploidy.

Claims (27)

1 - 16 . (canceled)

17 . A method for determining the fraction of fetal nucleic acids in a maternal sample comprising a mixture of fetal and maternal cfDNA, said method comprising:

(a) amplifying a plurality of polymorphic target nucleic acids in said mixture,

(b) performing massively parallel sequencing of at least a portion of the amplified product obtained in step (a), wherein said sequencing comprises providing a plurality of sequence tags; and

(c) based on said sequencing, determining said fraction.

18 . The method of claim 17 , wherein each of said plurality of polymorphic target nucleic acids comprises at least one single nucleotide polymorphism (SNP).

19 . The method of claim 17 , wherein each of said plurality of polymorphic target nucleic acid comprises at least one short tandem repeat (STR).

20 . The method of claim 17 , wherein said fetal and maternal genomic DNA is cell-free DNA (cfDNA).

21 . The method of claim 17 , wherein said massively parallel sequencing comprises sequencing-by-synthesis reversible dye terminators, sequencing-by-ligation, or single molecule sequencing.

22 . The method of claim 17 , wherein said maternal sample is selected from blood, plasma, serum, urine and saliva.

23 . The method of claim 17 , wherein determining said fraction comprises determining the number of fetal and maternal sequence tags mapped to a reference genome comprising said at least one polymorphic nucleic acid.

24 . The method of claim 17 , wherein said method is a fetal gender-independent method.

25 . The method of claim 17 , wherein said plurality of polymorphic nucleic acids are located on a plurality of different chromosomes.

26 . The method of claim 17 , wherein said plurality of different chromosomes are selected from chromosomes 1-22.

27 . The method of claim 17 , wherein said plurality of polymorphic sites are located on a chromosome other than chromosome 13, 18, 21, X or Y.

28 . The method of claim 17 , wherein said plurality of polymorphic nucleic acids comprises at least 3 informative polymorphic sites.

29 . The method of claim 17 , wherein said plurality of polymorphic nucleic acids comprises at least 10 informative polymorphic sites.

30 . The method of claim 18 , wherein said at least one SNP is a single SNP selected from rs560681, rs1109037, rs9866013, rs13182883, rs13218440, rs7041158, rs740598, rs10773760, rs4530059, rs7205345, rs8078417, rs576261, rs2567608, rs430046, rs9951171, rs338882, rs 10776839, rs9905977, rs1277284, rs258684, rs1347696, rs508485, rs9788670, rs8137254, rs3143, rs2182957, rs3739005, and rs530022.

31 . The method of claim 19 , wherein said at least one STR is selected from CSF1PO, FGA, TH01, vWA, D3S1358, D5S818, D7S820, D8S1179, D13S317, DI6S539, D18S51 ,D21S11, D2S1338, Penta D, Penta E, D22S1045, D20S1082, D20S482, DI8S853, DI 7S1301, DI 7S974, DI4S1434, DI2ATA63, DI 1S4463, DIOS1435, DIOS1248, D9S2157, D9S1122, D8S1115, D6S1017, D6S474, D5S2500, D4S2408, D4S2364, D3S4529, D3S3053, D2S1776, D2S441, D1S1677, D1S1627, and D1GATA113.

32 . A method for determining the fraction of fetal cell-free DNA (cfDNA) in a maternal sample comprising a mixture of fetal and maternal cfDNA, said method comprising:

(a) amplifying a plurality of polymorphic nucleic acids in said mixture of fetal and maternal nucleic acids, wherein each of said at least one polymorphic nucleic acid comprises a short tandem repeat (STR);

(b) determining the amount of fetal and maternal STR alleles at least one polymorphic nucleic acid; and

(c) determining said fraction using said amount of fetal and maternal STR alleles

33 , the method of claim 32 , further comprising preamplifying the mixture of fetal and maternal nucleic acids.

34 . The method of claim 32 , further comprising resolving the size of the STRs using capillary electrophoresis.

35 . The method of claim 32 , wherein the at least one STR is selected from CSF1PO, FGA, TH01, vWA, D3S1358, D5S818, D7S820, D8S1179, D13S317, D16S539, D18S51, D2S1338, Penta D, Penta E, D22S1045, D20S1082, D20S482, D18S853, D17S1301, D17S974, D14S1434, D12ATA63, D11S4463, D10S1435, D10S1248, D9S2157, D9S1122, D8S1115, D6S1017, D6S474, D5S2500, D4S2408, D4S2364, D3S4529, D3S3053, D2S1776, D2S441, D1S1677, D1S1627, and D1GATA113.

36 . A composition for determining the fraction of fetal cfDNA in a maternal sample, the composition comprising at least one set of primers for amplifying at least one polymorphic nucleic acid in said mixture.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2025
From: RAVA, RICHARD P.; HEILEK, GABRIELLE; COMSTOCK, DAVID A.; CHINNAPPA, MANJULA; HUNKAPILLER, MICHAEL
To: ARTEMIS HEALTH, INC.
Reel/Frame 072246/0423 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2025
From: CHUU, YUE-JEN
To: VERINATA HEALTH, INC.
Reel/Frame 072246/0429 →
CHANGE OF NAME Recorded Sep 13, 2025
From: ARTEMIS HEALTH, INC.
To: VERINATA HEALTH, INC.
Reel/Frame 072891/0863 →